查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1886346

表觀遺傳學市場－全球產業規模、佔有率、趨勢、機會和預測，按產品和服務、技術、最終用戶、地區和競爭格局分類，2020-2030年預測

Epigenetic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product & Service, By Technology, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024年全球表觀遺傳學市場規模為18.6億美元，預計到2030年將以8.17%的複合年成長率成長至29.8億美元。表觀遺傳學研究的是在不改變DNA序列的情況下發生的基因表現可遺傳變化，這些變化會影響基因的活化或沉默，進而影響細胞過程和疾病進展。該市場的成長主要受全球慢性疾病（尤其是癌症）盛行率上升的驅動，因為表觀遺傳修飾在癌症的發展和治療反應中起著至關重要的作用。

市場概覽
預測期 2026-2030
市場規模：2024年 18.6億美元
市場規模：2030年 29.8億美元
複合年成長率：2025-2030年 8.17%
成長最快的細分市場 試劑盒和試劑
最大的市場 北美洲

主要市場促進因素

全球癌症發病率和死亡率的不斷攀升顯著推動了表觀遺傳學市場的發展，因為表觀遺傳學改變在腫瘤發生和發展中發揮重要作用。表觀遺傳診斷和治療為早期檢測、預後和治療策略提供了新的途徑，滿足了迫切的醫療需求。

主要市場挑戰

先進的表觀遺傳學研究和診斷技術成本高昂，嚴重阻礙了全球表觀遺傳學市場的成長。這些巨額費用直接限制了小型研究機構和新興醫療機構的准入，使它們無法投資必要的設備、專業人員和進行大規模臨床試驗。

主要市場趨勢

表觀遺傳學在老化和長壽研究中的應用代表著一個巨大的發展領域，它超越了傳統的以疾病為中心的模式，轉而關注健康壽命的延長。表觀遺傳修飾日益被認為是老化過程和年齡相關疾病的根本促進因素，這促使人們投入大量資源來研究調節這些變化的干涉措施。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球表觀遺傳學市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品及服務分類（試劑盒及試劑、酵素、儀器及配件、軟體、服務）
    • 依技術分類（DNA甲基化、組蛋白甲基化、其他）
    • 按最終用戶分類（學術和研究機構、製藥公司和生物技術公司、合約研究組織、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美表觀遺傳學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲表觀遺傳學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區表觀遺傳學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲表觀遺傳學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲表觀遺傳學市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球表觀遺傳學市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Abcam Limited
  • Active Motif Inc
  • Hologic, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Qiagen NV
  • Thermo Fisher Scientific Inc
  • Novartis AG
  • Element Biosciences
  • Dovetail Genomics LLC

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 22713

The Global Epigenetic Market, valued at USD 1.86 Billion in 2024, is projected to experience a CAGR of 8.17% to reach USD 2.98 Billion by 2030. Epigenetics encompasses the study of heritable changes in gene expression that occur without altering the underlying DNA sequence, influencing how genes are activated or silenced to affect cellular processes and disease progression. The market's expansion is primarily driven by the increasing global prevalence of chronic diseases, particularly cancer, where epigenetic modifications play a crucial role in disease development and treatment response.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 1.86 Billion
Market Size 2030USD 2.98 Billion
CAGR 2025-20308.17%
Fastest Growing SegmentKits & Reagents
Largest MarketNorth America

Key Market Drivers

The increasing burden of cancer incidence and mortality rates globally significantly drives the epigenetic market, given the established role of epigenetic alterations in tumorigenesis and progression. Epigenetic diagnostics and therapeutics offer novel avenues for early detection, prognosis, and treatment strategies, responding to an urgent unmet medical need.

Key Market Challenges

The substantial costs associated with advanced epigenetic research and diagnostic technologies pose a significant impediment to the global epigenetic market's growth. These considerable expenses directly limit accessibility for smaller research institutions and emerging healthcare providers, preventing them from investing in necessary equipment, specialized personnel, and extensive clinical trials. Such financial barriers restrict the widespread adoption of innovative epigenetic tools and therapies, particularly in regions with constrained healthcare budgets, thereby slowing overall market penetration and expansion.

Key Market Trends

The application of epigenetics in aging and longevity research represents a substantial area of growth, moving beyond traditional disease-centric models to focus on healthspan extension. Epigenetic modifications are increasingly recognized as fundamental drivers of the aging process and age-related conditions, prompting significant investment in interventions to modulate these changes.

Key Market Players

  • Abcam Limited
  • Active Motif Inc
  • Hologic, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • Qiagen N.V.
  • Thermo Fisher Scientific Inc
  • Novartis AG
  • Element Biosciences
  • Dovetail Genomics LLC

Report Scope:

In this report, the Global Epigenetic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Epigenetic Market, By Product & Service:

  • Kits & Reagents
  • Enzymes
  • Instruments & Accessories
  • Software
  • Services

Epigenetic Market, By Technology:

  • DNA Methylation
  • Histone Methylation
  • Others

Epigenetic Market, By End user:

  • Academic and Research Institutes
  • Pharmaceutical Companies and Biotechnology Companies
  • Contract Research Organizations
  • Others

Epigenetic Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Epigenetic Market.

Available Customizations:

Global Epigenetic Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Epigenetic Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product & Service (Kits & Reagents, Enzymes, Instruments & Accessories, Software, Services)
    • 5.2.2. By Technology (DNA Methylation, Histone Methylation, Others)
    • 5.2.3. By End user (Academic and Research Institutes, Pharmaceutical Companies and Biotechnology Companies, Contract Research Organizations, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Epigenetic Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product & Service
    • 6.2.2. By Technology
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Epigenetic Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product & Service
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By End user
    • 6.3.2. Canada Epigenetic Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product & Service
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By End user
    • 6.3.3. Mexico Epigenetic Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product & Service
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By End user

7. Europe Epigenetic Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product & Service
    • 7.2.2. By Technology
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Epigenetic Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product & Service
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By End user
    • 7.3.2. France Epigenetic Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product & Service
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By End user
    • 7.3.3. United Kingdom Epigenetic Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product & Service
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By End user
    • 7.3.4. Italy Epigenetic Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product & Service
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By End user
    • 7.3.5. Spain Epigenetic Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product & Service
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By End user

8. Asia Pacific Epigenetic Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product & Service
    • 8.2.2. By Technology
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Epigenetic Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product & Service
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By End user
    • 8.3.2. India Epigenetic Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product & Service
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By End user
    • 8.3.3. Japan Epigenetic Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product & Service
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By End user
    • 8.3.4. South Korea Epigenetic Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product & Service
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By End user
    • 8.3.5. Australia Epigenetic Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product & Service
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By End user

9. Middle East & Africa Epigenetic Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product & Service
    • 9.2.2. By Technology
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Epigenetic Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product & Service
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By End user
    • 9.3.2. UAE Epigenetic Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product & Service
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By End user
    • 9.3.3. South Africa Epigenetic Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product & Service
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By End user

10. South America Epigenetic Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product & Service
    • 10.2.2. By Technology
    • 10.2.3. By End user
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Epigenetic Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product & Service
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By End user
    • 10.3.2. Colombia Epigenetic Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product & Service
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By End user
    • 10.3.3. Argentina Epigenetic Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product & Service
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By End user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Epigenetic Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Abcam Limited
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Active Motif Inc
  • 15.3. Hologic, Inc.
  • 15.4. F. Hoffmann-La Roche Ltd.
  • 15.5. Illumina, Inc.
  • 15.6. Qiagen N.V.
  • 15.7. Thermo Fisher Scientific Inc
  • 15.8. Novartis AG
  • 15.9. Element Biosciences
  • 15.10. Dovetail Genomics LLC

16. Strategic Recommendations

17. About Us & Disclaimer